Rozrolimupab, amixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia

February 11, 2022

Publications

>

Article

No

Rozrolimupab, amixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia

Publicated to:BLOOD. 120 (18): 3670-3676 - 2012-11-01 120(18), DOI: 10.1182/blood-2012-06-438804

Authors: Robak, Tadeusz; Windyga, Jerzy; Trelinski, Jacek; Prondzinski, Mario von Depka; Giagounidis, Aristoteles; Doyen, Chantal; Janssens, Ann; Teresa Alvarez-Roman, Maria; Jarque, Isidro; Loscertales, Javier; Rus, Gloria Perez; Hellmann, Andrzej; Jedrzejczak, Wieslaw Wiktor; Kuliczkowski, Kazimierz; Golubovic, Lana M; Celeketic, Dusica; Cucuianu, Andrei; Gheorghita, Emanuil; Lazaroiu, Mihaela; Shpilberg, Ofer; Attias, Dina; Karyagina, Elena; Svetlana, Kalinina; Vilchevska, Kateryna; Cooper, Nichola; Talks, Kate; Prabhu, Mukhyaprana; Sripada, Prasad; Bharadwaj, T P R; Naested, Henrik; Skartved, Niels J O; Frandsen, Torben P; Flensburg, Mimi F; Andersen, Peter S; Petersen, Jorgen

Affiliations

AMS Ukraine, Gusak Acad, Donetsk, Ukraine - Author

Apollo Hosp, AHERF Clin Trial Unit, Hyderabad, Andhra Pradesh, India - Author

Apollo Hospital - Author

Aysha Hosp Pvt Ltd, Chennai, Tamil Nadu, India - Author

Beilinson Med Ctr, Davidoff Ctr, Petah Tiqwa, Israel - Author

Bnai Zion Med Ctr, Dept Hematol, Haifa, Israel - Author

Bnai Zion Medical Center - Author

Brasov Country Hospital - Author

CHU Dinant Godinne | UCL Namur - Author

City Hosp 9, Dept Blood Syst Dis, Kiev, Ukraine - Author

City Hospital #9 - Author

Clin Ctr Zemun, Dept Haematol, Zemun, Serbia - Author

Clin Haematol & Clin Immunol, Nish, Serbia - Author

Clin Univ UCL Mt Godinne, Dept Hematol, Yvoir, Belgium - Author

Clinic for Haematology and Clinical Immunology - Author

Clinical Hospital Center Zemun - Author

Copernicus Mem Hosp, Lodz, Poland - Author

Country Hosp, Brasov, Romania - Author

Gdanski Uniwersytet Medyczny - Author

Gusak Academy of AMS Ukraine - Author

Hammersmith Hosp, Catherine Lewis Ctr, Dept Haematol, London, England - Author

Hammersmith Hospital - Author

Hosp Gen Univ Gregorio Maranon, Madrid, Spain - Author

Hosp La Paz, Madrid, Spain - Author

Hosp Univ La Princesa, Madrid, Spain - Author

Hosp Univ Politecn La Fe, Serv Hematol, Valencia, Spain - Author

Hospital General Universitario Gregorio Marañón - Author

Hospital Universitari I Politècnic la Fe - Author

Hospital Universitario de la Princesa - Author

Hospital Universitario La Paz - Author

Inst Hematol & Transfuzjol, Warsaw, Poland - Author

Institute of Haematology and Transfusion Medicine, Warsaw - Author

Institute of Oncology Cluj - Author

Kasturba Hospital - Author

Kasturba Med Coll Hosp, Manipal Ctr Clin Res, Mangalore, Karnataka, India - Author

Kasturba Medical College, Manipal - Author

Katedra & Klin Hematol Onkol & Chorob, Warsaw, Poland - Author

Klin Hematol Nowotworow Krwi & Transplantacji Szp, Wroclaw, Poland - Author

KU Leuven– University Hospital Leuven - Author

Med Univ Gdansk, Dept Hematol & Transplantol, Gdansk, Poland - Author

Med Univ Lodz, Dept Hematol, Pabianicka 62, PL-93513 Lodz, Poland - Author

Medical University of Lodz - Author

Newcastle Biomed Clin Res Platforms Level 6, Newcastle Upon Tyne, Tyne & Wear, England - Author

Onkologii i Chorob - Author

Prof Dr Ion Chiricuta Oncol Inst, Hematol Clin, Cluj Napoca, Romania - Author

Pvt. Ltd. - Author

Rabin Medical Center Israel - Author

St Johannes Hosp, Duisburg, Germany - Author

St. Johannes-Hospital Duisburg - Author

State Healthcare Institution (SHI) - Author

State Inst Healthcare, St Petersburg, Russia - Author

Symphogen AS - Author

Symphogen AS, Lyngby, Denmark - Author

UZ Leuven, Dept Haematol, Louvain, Belgium - Author

Werlhof Inst, Hannover, Germany - Author

Werlhof-Institut - Author

Wroclaw Medical University - Author

Abstract

Rozrolimupab, a recombinant mixture of 25 fully human RhD-specific monoclonal antibodies, represents a new class of recombinant human antibody mixtures. In a phase 1 or 2 dose escalation study, RhD+ patients (61 subjects) with primary immune thrombocytopenia received a single intravenous dose of rozrolimupab ranging from 75 to 300 μg/kg. The primary outcome was the occurrence of adverse events. The principal secondary outcome was the effect on platelet levels 7 days after the treatment. The most common adverse events were headache and pyrexia, mostly mild, and reported in 20% and 13% of the patients, respectively, without dose relationship. Rozrolimupab caused an expected transient reduction of hemoglobin concentration in the majority of the patients. At the dose of 300 μg/kg platelet responses, defined as platelet count ≥ 30 × 109/L and an increase in platelet count by > 20 × 109/L from baseline were observed after 72 hours and persisted for at least 7 days in 8 of 13 patients (62%). Platelet responses were observed within 24 hours in 23% of patients and lasted for a median of 14 days. Rozrolimupab was well tolerated and elicited rapid platelet responses in patients with immune thrombocytopenia and may be a useful alternative to plasma-derived products. This trial is registered at www.clinicaltrials.gov as #NCT00718692. © 2012 by The American Society of Hematology.

Keywords

Astronomia / físicaBiochemistryBiodiversidadeBiotecnologíaCell biologyCiências ambientaisCiências biológicas iCiências biológicas iiCiências biológicas iiiEngenharias ivFarmaciaGeneral medicineHematologyImmunologyInterdisciplinarMedicina iMedicina iiMedicina iiiSaúde coletiva

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal BLOOD due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2012, it was in position 3/67, thus managing to position itself as a Q1 (Primer Cuartil), in the category Hematology.

From a relative perspective, and based on the normalized impact indicator calculated from World Citations provided by WoS (ESI, Clarivate), it yields a value for the citation normalization relative to the expected citation rate of: 1.33. This indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 14, 2024)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

Weighted Average of Normalized Impact by the Scopus agency: 1.32 (source consulted: FECYT Feb 2024)
Field Citation Ratio (FCR) from Dimensions: 6.72 (source consulted: Dimensions Jul 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-07-18, the following number of citations:

WoS: 45
Scopus: 47

Impact and social visibility

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Belgium; Denmark; Germany; India; Israel; Oman; Poland; Rumanía; Russia; Serbia; Ukraine; United Kingdom.

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: Last Author (ALVAREZ ROMAN, MARIA TERESA).

Indexed in

License and use

Citations

Altmetrics

Impact on the Sustainable Development Goals (SDGs)

Analysis of institutional authors

Share

Rozrolimupab, amixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia

Affiliations

Abstract

Keywords

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

Impact and social visibility

Leadership analysis of institutional authors